EP Patent

EP2606879A1 — Multiple unit pellet tablet formulation comprising an opioid

Assigned to Hexal AG · Expires 2013-06-26 · 13y expired

What this patent protects

The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets w…

USPTO Abstract

The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets wherein the active agent is an opioid. The sustained-release pellets are suitable for the preparation of a multiple unit pellet tablet formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2606879A1
Jurisdiction
EP
Classification
Expires
2013-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Hexal AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.